YOKNEAM, ISRAEL--(Marketwired - May 2, 2013) - Lumenis Ltd., will unveil a new surgical teaching simulator for Holmium Laser Enucleation of the Prostate (HoLEP), which is designed to dramatically shorten the surgical learning curve for urologists to practice this gold standard treatment for Benign Prostatic Hyperplasia (BPH).
Lumenis will be exhibiting the HoLEP simulator, along with its VersaPulse® PowerSuite™ 100 Watt holmium laser at the American Urological Association (AUA) Congress taking place in San Diego, CA, from May 4th-7th, 2013, at Booth #3323.
BPH is very common in men age 50 and older and is primarily a quality of life condition associated with progressive lower urinary tract symptoms, but if symptoms are severe and untreated it can lead to serious medical conditions, such as: incontinence, kidney damage, bladder damage, urinary tract infections and bladder stones. Histological evidence has shown that nearly all men eventually develop BPH by the age of 90. HoLEP is considered a gold standard treatment for BPH and represents a successful, safe and durable treatment for this condition with a lower recurrence rate on long-term follow-up.1
Reoperation rates for HoLEP are only 1%, compared to significantly higher reoperation rates for other treatment modalities: 50% for Photo-Selective Vaporization of the Prostate (PVP) and 10% for Transurethral Resection of the Prostate (TURP)2. Therefore, facilitating surgeon's ability to learn the laser enucleation procedure faster will provide a better long-term outcome for their patients.
Although the BPH treatment guidelines recommend HoLEP as a surgical treatment,3 the lack of hands-on courses and training for the procedure is a major obstacle for its broad adoption. The new HoLEP simulator helps overcome this barrier by enabling Urologists to practice HoLEP on a simulator that demonstrates the prostate in close resemblance to a human prostate.
"We experience significant physician interest in learning how to perform the procedure, using the new HoLEP simulator. This demand is being fueled by a growing body of clinical evidence that validates the superior clinical outcomes and long-term durability of the HoLEP procedure. We look forward to sharing this unique technology with the conference attendees, during sessions with experts and hands-on training," said Mr. Elad Benjamin, Vice President & General Manager of the Lumenis Surgical Business Unit.
Lumenis encourages Urologists to try the HoLEP procedure by attending the HoLEP simulation sessions taking place May 4th-6th, at the Lumenis AUA booth #3323.
Lumenis will also showcase the VersaPulse PowerSuite holmium 100 Watt laser at the conference. This versatile product enables superior clinical outcomes for a wide range of conditions. These conditions include laser lithotripsy for stones of all types and composition, a variety of different BPH treatment techniques, as well as other soft tissue applications, such as tumors and strictures. Lumenis holmium laser is capable of treating the whole patient.
Lumenis also offers a variety of holmium & Nd:YAG laser systems and fibers to meet Urology's varying clinical needs in both office and hospital settings.
About Lumenis
Lumenis, the world's largest medical laser company, is a global developer, manufacturer and distributor of laser and light-based devices for surgical, aesthetic and ophthalmic applications, with more than 900 employees worldwide. Lumenis has 265 registered patents, over 260 FDA clearances, an install base of over 80,000 systems and presence in over 80 countries. Lumenis endeavors to bring the finest state of the art technology products to the market, fulfilling the highest standards of excellence, quality and reliability, delivering premium value and service to its customers. The name Lumenis is derived from a Latin word meaning "Light of Life." Highlighting the light is the basis of our technologies used to enhance life. For more information about Lumenis and its products, please visit: www.lumenis.com.
Lumenis®, the Lumenis logo, VersaPulse & PowerSuite are trademarks or registered trademarks of Lumenis.
1. Hazem M. Elmansy, Ahmed Kotb and Mostafa M. Elhilali, Holmium Laser Enucleation of the Prostate: Long-Term Durability of Clinical Outcomes and Complication Rates During 10 Years of Followup, The Journal of Urology, 2011, 186:1972-1976.
2. HoLEP vs. TURP Reoperation Rates and Cost Effectiveness, Gilling PJ presented material at WCE and AUA 2009.
3. Ehab A. Elzayat, Mostafa M. Elhilali, Holmium Laser Enucleation of the Prostate (HoLEP): Long-Term Results, Reoperation Rate, and Possible Impact of the Learning Curve, European Urology,2007, 52(1465-1472).
Contact Information:
For further information:
Jeff Jacomowitz
Lazar Partners Ltd.
(212) 867 1762